Problems meeting basic needs moderate the association between the APOE epsilon4 allele and cognitive decline

Natalie Sachs-Ericsson1, Elizabeth Corsentino, Nicole Collins

  • 1Department of Psychology, Florida State University, Tallahassee, Florida 32306-4301, USA. sachs@psy.fsu.edu

Aging & Mental Health
|December 1, 2009
PubMed

Insights

Problems meeting basic needs amplify cognitive decline risk in individuals with the ApolipoproteinE epsilon4 (APOE epsilon4) allele, suggesting potential intervention targets.

Area of Science:

  • Neuroscience
  • Genetics
  • Gerontology

Background:

  • The ApolipoproteinE epsilon4 (APOE epsilon4) allele is a known genetic risk factor for cognitive decline (CD).
  • However, its impact on CD varies among individuals, suggesting the involvement of other modifying factors.
  • Socioeconomic factors, such as problems meeting basic needs (BN), may play a crucial role.

Purpose of the Study:

  • To investigate whether problems meeting basic needs (BN) modify the relationship between the APOE epsilon4 allele and cognitive decline (CD).
  • To determine if the APOE epsilon4 allele and BN interact synergistically to influence cognitive functioning in older adults.

Main Methods:

  • Community-dwelling older adults from the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE) were studied.
  • Cognitive functioning was assessed at two time points, 3 years apart, controlling for baseline cognitive status.
  • APOE genotyping was performed, and problems meeting basic needs were evaluated.

Main Results:

  • Both the APOE epsilon4 allele and problems meeting BN independently predicted cognitive decline.
  • A significant interaction was observed: the influence of BN on CD was greater for individuals carrying the APOE epsilon4 allele.
  • Other socioeconomic indicators did not show this interaction effect with the APOE epsilon4 allele.

Conclusions:

  • A synergistic effect exists between perceived problems meeting basic needs and the APOE epsilon4 allele in influencing cognitive functioning.
  • While genetic risk factors are immutable, addressing resource deprivation through interventions may mitigate cognitive decline risk.
Abstract

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...